RG
JAZZ icon

Redmile Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Redmile Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-341,882
Closed -$42.4M – 72
2023
Q2 		$42.4M Buy
341,882
+6,723
+2% +$905K 1.63% 19
2023
Q1 		$49M Buy
335,159
+16,214
+5% +$2.4M 2.13% 15
2022
Q4 		$50.8M Buy
318,945
+237,481
+292% +$34.8M 2.08% 16
2022
Q3 		$10.9M Sell
81,464
-11,800
-13% -$1.79M 0.42% 49
2022
Q2 		$14.6M Sell
93,264
-21,500
-19% -$3.31M 0.56% 45
2022
Q1 		$17.9M Buy
114,764
+16,700
+17% +$2.42M 0.56% 45
2021
Q4 		$12.5M Sell
98,064
-763,337
-89% -$100M 0.28% 56
2021
Q3 		$112M Buy
861,401
+1,300
+0.2% +$196K 1.96% 18
2021
Q2 		$153M Buy
860,101
+30,942
+4% +$5.36M 2.26% 12
2021
Q1 		$136M Buy
+829,159
New +$136M 1.92% 14
2019
Q4 		– Sell
-187,599
Closed -$24M – 70
2019
Q3 		$24M Buy
187,599
+19,212
+11% +$2.58M 0.8% 40
2019
Q2 		$24M Sell
168,387
-101,093
-38% -$13.6M 0.68% 44
2019
Q1 		$38.5M Buy
269,480
+132,800
+97% +$17.3M 1.13% 29
2018
Q4 		$16.9M Buy
136,680
+135,090
+8,496% +$20M 0.68% 46
2018
Q3 		$267K Hold
1,590
– – 0.01% 78
2018
Q2 		$274K Buy
+1,590
New +$260K 0.01% 74
2015
Q4 		– Sell
-1,769
Closed -$235K – 62
2015
Q3 		$235K Sell
1,769
-149,097
-99% -$25.7M 0.02% 55
2015
Q2 		$26.6M Buy
150,866
+50,866
+51% +$9.14M 2.18% 16
2015
Q1 		$17.3M Buy
+100,000
New +$17.2M 1.55% 23
2014
Q2 		– Sell
-142,886
Closed -$19.8M – 54
2014
Q1 		$19.8M Sell
142,886
-39,675
-22% -$5.97M 2.37% 18
2013
Q4 		$23.1M Buy
+182,561
New +$18.9M 2.85% 8

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Redmile Group's JAZZ Position: Q3 2023 in Review

Redmile Group sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 341,882 shares — an estimated $42.4M sold.

Redmile Group first reported a position in JAZZ in Q4 2013 and held it in 21 quarters. The position peaked at $153M in Q2 2021. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

  • Redmile Group reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Redmile Group sold 341,882 Jazz Pharmaceuticals shares in Q3 2023, an estimated $42.4M.
  • Redmile Group first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 21 quarters.
  • Redmile Group's Jazz Pharmaceuticals position peaked at $153M in Q2 2021.
  • 484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Redmile Group's 13F filing for Q3 2023, filed 14 Nov 2023.